HDFC Life Insurance decreased its stake in Lupin Limited from 1.30% to 1.10%, selling 921,491 shares. The value of the sold shares was approximately ₹222.06 crore at a price of ₹2406.90 per share.
An innovation-led pharmaceutical company headquartered in Mumbai, Lupin develops and commercializes a broad range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company operates as a transnational enterprise, serving customers across more than 100 markets including the United States, India, South Africa, Asia Pacific, Latin America, Europe, and the Middle East regions.
HDFC Life Insurance Company Limited, institutional investor in Indian equities
